Program
mazdutide
Also written as “IBI362”, “LY3305677” and “Mazdutide”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 208 open or running | phase 3since Oct 19, 2022 | Jun 5, 2020 | Dec 31, 2026phase 3 · NCT06884293 |
| Eli Lilly | 71 open or running | phase 2since Nov 6, 2023 | Nov 21, 2016 | Sep 2027phase 2 · NCT06143956 |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseInnovent licensed it from Lilly, for China.Announced Aug 21, 2019 · Source: Innovent (release), Aug 21, 2019
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 21, 2016.
- Nov 15, 2022Phase 1 study in OverweightEli Lilly · NCT05623839 · 32 enrolled · United States
- Nov 17, 2022Phase 3 study in Diabetes Mellitus, Type 2Innovent Biologics · NCT05628311 · 319 enrolled · China
- Mar 20, 20232 phase 1 studiesInnovent Biologics · NCT05815680, NCT05793450
- Nov 6, 20232 phase 2 studies in ObesityEli Lilly · NCT06143956, NCT06124807
- Dec 1, 20232 phase 3 studiesInnovent Biologics · NCT06164873, NCT06184568
- Jul 25, 2024Phase 1 study in Adolescents With ObesityInnovent Biologics · NCT06536023 · 36 enrolled · China
- Feb 5, 2025Phase 2 study in AlcoholismEli Lilly · NCT06817356 · 308 enrolled · United States
- Feb 19, 2025Phase 2 study in ObesityInnovent Biologics · NCT06862908 · 141 enrolled · China
- Mar 11, 2025Phase 3 study in OverweightInnovent Biologics · NCT06884293 · 479 enrolled · China
- Apr 7, 2025Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)Innovent Biologics · NCT06937749 · 181 enrolled · China
- Apr 9, 2025Phase 3 study in Sleep Apnea SyndromesInnovent Biologics · NCT06931028 · 260 planned · China
- May 8, 2025Phase 2 study in ObesityInnovent Biologics · NCT07000955 · 98 enrolled · China
- Nov 19, 2025Phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesInnovent Biologics · NCT07255209 · 180 planned · China
- Feb 27, 2026Phase 3 study in OverweightInnovent Biologics · NCT07469800 · 336 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in OverweightInnovent Biologics · NCT06884293
- May 7, 2027Primary completion: phase 3 study in Sleep Apnea SyndromesInnovent Biologics · NCT06931028
- Sep 2027Primary completion: phase 2 study in ObesityEli Lilly · NCT06143956
- Oct 31, 2027Primary completion: phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesInnovent Biologics · NCT07255209
TargetBeta
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07469800Overweight · China | 3 | Recruiting | Innovent Biologics | Aug 1, 2026 | 336 |
| NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities · China | 3 | Recruiting | Innovent Biologics | Oct 31, 2027 | 180 |
| NCT07000955Obesity · China | 2 | Active, not recruiting | Innovent Biologics | Sep 30, 2026 | 98 |
| NCT06931028Sleep Apnea Syndromes · China | 3 | Recruiting | Innovent Biologics | May 7, 2027 | 260 |
| NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH) · China | 2 | Active, not recruiting | Innovent Biologics | Sep 23, 2026 | 181 |
| NCT06884293Overweight · China | 3 | Active, not recruiting | Innovent Biologics | Dec 31, 2026 | 479 |
| NCT06862908Obesity · China | 2 | Active, not recruiting | Innovent Biologics | Sep 24, 2026 | 141 |
| NCT06817356Alcoholism · United States | 2 | Completed | Eli Lilly | Mar 19, 2026 | 308 |
| NCT06536023Adolescents With Obesity · China | 1 | Completed | Innovent Biologics | Jul 22, 2025 | 36 |
| NCT06184568Diabetes Mellitus, Type 2 · China | 3 | Completed | Innovent Biologics | Sep 17, 2025 | 349 |
| NCT06164873Obesity · China | 3 | Active, not recruiting | Innovent Biologics | Jun 27, 2025 | 462 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Eli Lilly | Sep 2027 | 1,481 |
| NCT06124807Obesity · United States | 2 | Completed | Eli Lilly | Jan 22, 2025 | 179 |
| NCT05815680Overweight Subjects · China | 1 | Completed | Innovent Biologics | Aug 18, 2023 | 48 |
| NCT05793450Renal Insufficiency · China | 1 | Completed | Innovent Biologics | Sep 18, 2023 | 20 |
| NCT05628311Diabetes Mellitus, Type 2 · China | 3 | Completed | Innovent Biologics | Oct 25, 2023 | 319 |
| NCT05623839Overweight · United States | 1 | Completed | Eli Lilly | Jun 27, 2023 | 32 |
| NCT05607680Obesity Or Overweight · China | 3 | Completed | Innovent Biologics | Aug 21, 2023 | 610 |
| NCT05606913Diabetes Mellitus, Type 2 · China | 3 | Completed | Innovent Biologics | Jan 26, 2024 | 731 |
| NCT04965506Diabetes Mellitus, Type 2 · China | 2 | Completed | Innovent Biologics | Apr 28, 2022 | 252 |
| NCT04904913Overweight/ Obesity · China | 2 | Completed | Innovent Biologics | Mar 29, 2023 | 328 |
| NCT04773977Overweight · China | 1 | Completed | Innovent Biologics | Mar 9, 2021 | 24 |
| NCT04466904Diabetes Mellitus, Type 2 · China | 2 | Completed | Innovent Biologics | May 28, 2021 | 42 |
| NCT04440345Overweight · China | 2 | Completed | Innovent Biologics | Jun 16, 2021 | 60 |
| NCT03928379Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Eli Lilly | Jul 8, 2021 | 24 |
| NCT03325387Healthy · United Kingdom | 1 | Completed | Eli Lilly | Aug 3, 2018 | 56 |
| NCT02972645Healthy · United Kingdom | 1 | Completed | Eli Lilly | Jul 14, 2017 | 66 |
How it is read
Names in the registry
- “IBI362”, 19 entries
- “LY3305677”, 5 entries
- “Mazdutide”, 2 entries
- “IBI362 liquid formulation”, 1 entry
- “IBI362 lyophilized powder”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 6 studies
- Overweight, 2 studies
- Fatty Liver, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.